Search clinical trials for: REGN5668

Total 83 results

Regeneron Pharmaceuticals

Recruiting

Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Food Allergy

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers

Healthy

United States
M.D. Anderson Cancer Center

Recruiting

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

Prostate Cancer | Radical Prostatectomy

United States
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE)

Dermatitis, Atopic

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

Atopic Dermatitis

Germany, Poland, United Kingdom, Hungary, Canada, Czechia
Regeneron Pharmaceuticals

Available

Compassionate Use of Dupilumab

Bullous Pemphigoid | Pediatric Asthma | Pediatric Eosinophilic Esophagitis (EoE) | Pediatric and Adolescent Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Atopic Dermatitis

United States, Canada, Czechia, Germany, Hungary, Poland, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Poland, Germany, France, Hungary, Czechia
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Germany, Poland, Japan, Canada, Hungary, Czechia
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD) (SOLO-CONTINUE)

Atopic Dermatitis
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) (EoE KIDS)

Eosinophilic Esophagitis (EoE)

United States, Canada
Sanofi

Recruiting

A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment (AD-BEASCUITS)

Dermatitis Atopic

Italy
Regeneron Pharmaceuticals
Sanofi

Recruiting

Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

Asthma | Atopic Dermatitis (AD)

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

Allergic Bronchopulmonary Aspergillosis

United States, Hungary, Bulgaria, France, Germany, Japan, Netherlands, Poland, Romania, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

Atopic Dermatitis

Hungary, Netherlands, Spain, United Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Lithuania, New Zealand, ... and more
Regeneron Pharmaceuticals
Sanofi

Available

Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

Bullous Pemphigoid
Regeneron Pharmaceuticals
Sanofi

Completed

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

Conjunctivitis | Atopic Dermatitis

United States
Sanofi

Recruiting

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine (CLEAR PN)

Prurigo Nodularis

Germany
Regeneron Pharmaceuticals
Sanofi

Recruiting

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

Atopic Dermatitis | Adverse Pregnancy Outcomes

United States
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) (AROMA)

Chronic Rhinosinusitis With Nasal Polyposis

United States, Italy, Canada, Japan, Germany, Netherlands
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Registry of Asthma Patients Initiating DUPIXENT® (RAPID)

Asthma

United States, United Kingdom, Canada, France, Puerto Rico, Japan, Spain, Denmark, Italy, Sweden
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

Peanut Allergy

United States, Canada
Regeneron Pharmaceuticals

Available

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Multiple Myeloma
Regeneron Pharmaceuticals

Terminated

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

Pain | Osteoarthritis of the Knee

United States, Georgia, Moldova, Republic of, Poland, Ukraine
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

Healthy Volunteer

Belgium
Sanofi
Regeneron Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.

Healthy Volunteers

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects

Healthy

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers

Healthy

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis (PELISTAD-EX2)

Dermatitis Atopic

United States, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)

Chronic Rhinosinusitis With Nasal Polyps

Japan
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Atopic Dermatitis

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects

Healthy

Japan
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (GLOBOSTAD)

Dermatitis Atopic

Spain, Czechia, Italy, Israel, Argentina, Australia, Austria, Belgium, Colombia, Finland, France, Greece, Japan, Kuwait, Mexico, Netherlands, Norway, Portugal, Russian Federation, Saudi Arabia, Taiwan, United Arab Emirates
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis (PELISTAD)

Dermatitis Atopic

United States, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults

Healthy Volunteers

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis (DIFFEREN-STAD)

Dermatitis Atopic

United States, Germany
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab Skin Barrier Function Study in Atopic Dermatitis (BALISTAD)

Atopic Dermatitis

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

Asthma

Spain, Canada, Denmark, Belgium, Japan, Korea, Republic of, Mexico, United States, Israel, Brazil, Australia, France, Germany, United Kingdom, Argentina, Chile, Colombia, Hungary, Italy, Netherlands, Poland, Romania, Russian Federation and more
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

United States, Belgium
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (LINKER-AL2)

Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals

Not yet recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (LINKER-MGUS1)

Monoclonal Gammopathy of Undetermined Significance (MGUS) | Smoldering Multiple Myeloma (SMM)
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Clear Cell Renal Cell Carcinoma (ccRCC)

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Eosinophilic Esophagitis

United States, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Smoldering Multiple Myeloma (SMM)

Spain
Regeneron Pharmaceuticals

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

Multiple Myeloma

United States, France
Regeneron Pharmaceuticals

Recruiting

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma (LINKER-MM1)

Multiple Myeloma

Belgium, United States, Japan, Korea, Republic of, Germany, Spain, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Moderate to Severe Atopic Hand and Foot Dermatitis

United States, Germany, Japan, Poland
Regeneron Pharmaceuticals
Sanofi

Completed

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Dermatitis

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

Asthma

United States, Argentina, Belgium, Canada, France, Germany, Israel, Japan, Netherlands, South Africa
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Eosinophilic Esophagitis

United States

3

Subscribe